BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile

 

Genomic Health, Inc. 

301 Penobscot Drive

Redwood City  California  94063  U.S.A.
Phone: 650-556-9300 Fax: 650-556-1132


SEARCH JOBS



Genomic Health, Inc. (NASDAQ: GHDX) is the world’s leading provider of genomic-based diagnostic tests that address the overtreatment of early stage cancer, one of the greatest issues in healthcare today. The company is applying its world-class scientific and commercial expertise and infrastructure to lead the translation of massive amounts of genomic data into clinically-actionable results throughout the cancer patient’s journey, from screening and surveillance, to diagnosis, to treatment selection and monitoring. Genomic Health’s lead product, the Oncotype DX® breast cancer test, has been shown to predict the likelihood of chemotherapy benefit as well as recurrence in invasive breast cancer and has been shown to predict the likelihood of recurrence in ductal carcinoma in situ (DCIS). In addition to this widely adopted test, Genomic Health provides the Oncotype DX colon cancer test, the first multi-gene expression test developed for the assessment of risk of recurrence in patients with stage II and stage III disease, and the Oncotype DX prostate cancer test, which predicts disease aggressiveness in men with low risk disease. As of June 30, 2013, more than 19,000 physicians in over 70 countries had ordered more than 375,000 Oncotype DX tests. The company is based in Redwood City, California with European headquarters in Geneva, Switzerland.

For more information, please visit, www.GenomicHealth.com
and follow the company on Twitter: @GenomicHealth. To learn more about Oncotype DX tests, visit: www.OncotypeDX.com
, www.mybreastcancertreatment.org and www.myprostatecancertreatment.org.


 Key Statistics


Email:
Ownership: Public

Web Site: Genomic Health, Inc.
Employees:
Symbol: GHDX
 



Industry
Medical Device






 Company News
Genomic Health, Inc. (GHDX) Release: Results from Second Oncotype DX Prostate Cancer Test Clinical Validation And First Decision Impact Study To Be Published In European Urology And Urology Practice, Respectively 11/19/2014 12:26:52 PM
Genomic Health, Inc. (GHDX) Announces Third Quarter 2014 Financial Results And Reports Continued Growth In U.S. Invasive Breast Cancer Business 11/5/2014 7:36:08 AM
Genomic Health, Inc. (GHDX) To Present At The Credit Suisse Annual Healthcare Conference 11/4/2014 9:07:29 AM
Genomic Health, Inc. (GHDX) To Announce Third Quarter 2014 Financial Results And Host Conference Call On Tuesday, November 4, 2014 10/28/2014 7:59:26 AM
Genomic Health, Inc. (GHDX) Release: The Oncotype DX® Test And Precision Oncology: New Data Presented At ESMO Further Demonstrate Genomic Health’s Successful Approach To Understanding Tumor Biology 9/29/2014 12:57:17 PM
Genomic Health, Inc. (GHDX) Announces Positive Results From Latest Clinical Validation Study Of Oncotype DX® As Predictor Of Near- And Long-Term Outcomes In Racially Diverse Group Of Prostate Cancer Patients 9/29/2014 9:46:34 AM
Genomic Health, Inc. (GHDX) Announces Oral Presentation Of Positive Results From Second Large, Independent Clinical Validation Study Of Oncotype DX® In DCIS Breast Cancer At 2014 CTRC-AACR San Antonio Breast Cancer Symposium (SABCS) 9/26/2014 7:42:57 AM
Genomic Health, Inc. (GHDX) Release: New Survey Reveals Alarming Lack Of Understanding Of Prostate Cancer, Inspires "Your Prostate Your Decision" Education Campaign With Baseball Hall-Of-Famer Joe Torre 9/24/2014 8:23:01 AM
Genomic Health, Inc. (GHDX) Announces Publication Of Colon Cancer Cost-Effectiveness Study In Pharmacoeconomics 9/12/2014 9:50:17 AM
Genomic Health, Inc. (GHDX) Announces Presentation Of Positive Results From Latest Prostate Cancer Clinical Validation Study At The European Society For Medical Oncology (ESMO) 2014 Congress 9/9/2014 8:09:28 AM
12345678910...